Board of Directors

JESSE JAYNES Chairman of the Board

Dr. Jesse Jaynes, Ph.D., co-founded Genvor, and he leads the research for Genvor and manages ongoing, critical communication with our outside research and development partners and associations. Dr. Jaynes is one of the world’s leading authorities on therapeutic peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing, and oncology. Dr. Jaynes’ research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.

CLAYTON YATES Board Member

Dr. Clayton Yates, Ph.D., co-founded Genvor. His research is currently funded by the National Cancer Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also scientist at Tuskegee University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and pancreatic cancers. Dr. Yates received his initial training at the University of Pittsburgh School of Medicine in the Department of Cellular and Molecular Pathology. He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the McGowan Institute for Regenerative Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral training at Emory University School of Medicine in the Department of Molecular Urology.

JUDITH S. MILLER Board Member

Judith S. Miller is a member of the Florida Bar, living in Chapel Hill, North Carolina. Judith was a seed-investor in the precursor company that became the current Genvor Incorporated. The Board asked her to step into an Interim CEO Role in 2023, later transitioning to Chief Business Officer with the January 2024 appointment of Chad Pawlak as CEO. Judith has served as a Business Strategist for both domestic and international entities, is a Real Estate Developer, and an award-winning Film & Theater Producer. Judy earned both her BAED and JD from the University of Florida where she also was an Instructor of Business Law.